CJC-1295 No DAC + Ipamorelin Research-Grade Lyophilized Peptide Blend 10mg
The CJC-1295 No DAC + Ipamorelin Research-Grade Lyophilized Peptide Blend combines two extensively studied growth hormone secretagogues into a single research formulation. Each laboratory vial contains 5 mg of CJC-1295 No DAC and 5 mg of Ipamorelin, supplied as a high-purity lyophilized powder suitable for scientific and laboratory investigations.
Researchers have shown significant interest in these peptides due to their distinct yet complementary mechanisms of action. While both compounds are commonly categorized as growth hormone secretagogues, they interact with different biological pathways, making them a frequent subject of investigation in endocrine, metabolic, and peptide signaling research.
CJC-1295 No DAC
CJC-1295 No DAC is a modified analogue of Growth Hormone Releasing Hormone (GHRH). Unlike the longer-acting DAC version, the No DAC variant is designed for shorter activity and is often selected in research environments examining pulsatile signaling and receptor-mediated responses.
Scientists frequently investigate CJC-1295 No DAC for its interaction with GHRH receptors and its role in regulating growth hormone signaling pathways. Because of its shorter duration of action compared to DAC-modified analogues, researchers may utilize it when studying temporal hormone responses and endocrine feedback mechanisms.
The peptide continues to attract interest in studies involving hormone regulation, receptor activity, cellular communication, and peptide pharmacology.
Ipamorelin
Ipamorelin is a synthetic pentapeptide belonging to the growth hormone secretagogue family. It was developed as a selective ghrelin receptor agonist and has been widely investigated for its ability to stimulate growth hormone release pathways while demonstrating high receptor selectivity. Research has identified Ipamorelin as one of the more selective compounds within this peptide class.
Due to its unique receptor profile, Ipamorelin has become a frequent subject of scientific investigation involving endocrine signaling, peptide-receptor interactions, and growth hormone secretagogue biology.
Researchers continue to evaluate the compound in laboratory models exploring hormone regulation, metabolic pathways, cellular signaling, and receptor-mediated activity.
Research Interest in the Combination
One reason investigators frequently study CJC-1295 No DAC and Ipamorelin together is that the two compounds act through different signaling pathways. CJC-1295 No DAC primarily targets the GHRH receptor pathway, while Ipamorelin acts through growth hormone secretagogue receptors associated with ghrelin signaling. This complementary activity has generated ongoing interest in research involving endocrine regulation and growth hormone secretion pathways.
By examining both compounds simultaneously, researchers can investigate how distinct receptor systems interact within controlled laboratory environments. Studies commonly focus on receptor activation patterns, intracellular signaling cascades, endocrine responses, and growth hormone secretagogue biology.
The combination remains one of the most recognized peptide pairings within growth hormone secretagogue research and continues to be utilized in a variety of experimental models.
Quality and Analytical Verification
Each vial contains 10 mg total peptide content consisting of 5 mg CJC-1295 No DAC + 5 mg Ipamorelin. The material is supplied as a lyophilized powder and manufactured according to strict quality standards.
Independent third-party analytical testing is utilized to verify identity and purity specifications. Every vial is sealed and labeled for laboratory identification purposes.
Third-Party Research Reference
Ipamorelin, the first selective growth hormone secretagogue:
https://pubmed.ncbi.nlm.nih.gov/9849822/
Research Use Only
This product is intended exclusively for laboratory research and analytical purposes.
Not for human or veterinary use.
Reviews
There are no reviews yet.